65 results on '"Hanauer, S. B."'
Search Results
2. P734 Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study
3. P689 Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in UC clinical trials
4. P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
5. P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease
6. P874 Impact of immunogenicity on clinical outcomes in patients with Crohn’s disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study
7. P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study
8. P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study
9. P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study
10. P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
11. DOP81 Baseline whole-blood gene expression of TREM1 does not predict clinical or endoscopic outcomes following adalimumab treatment in patients with Ulcerative Colitis or Crohn’s Disease in the SERENE studies
12. P457 Long-term cumulative safety of ustekinumab in bionaive patients with Crohn’s Disease and Ulcerative Colitis
13. P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study
14. OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
15. State-of-the-Art Lecture: The future of biologic therapy in Asia
16. Induction of remission in ulcerative colitis
17. Potential human models of IBD
18. P343 Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study
19. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
20. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study)
21. P544 Histological remission following ozanimod treatment is associated with concurrent clinical remission and endoscopic mucosal healing: Results from the TOUCHSTONE study
22. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis
23. Management of perianal Crohn’s disease
24. Top-down therapy for inflammatory bowel disease
25. Randomised clinical trial: individualised vs. weight‐based dosing of azathioprine in Crohn's disease
26. Randomised clinical trial: the safety and tolerability ofTrichuris suisova in patients with Crohn's disease
27. Ulcerative colitis
28. Commentary: pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis
29. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn’s disease
30. Evaluation of a daily practice composite score for the assessment of Crohn’s disease: the treatment impact of certolizumab pegol
31. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study
32. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease
33. Review article: evolving concepts in treatment and disease modification in ulcerative colitis
34. Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohnʼs Disease Who Failed Prior Anti-TNFα Therapy
35. Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteriods for the Induction of Sustained Response and Remission in Patients with Crohnʼs Disease
36. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
37. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
38. European evidence-based consensus on the diagnosis and management of Crohn's disease
39. Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohnʼs Disease
40. Adalimumab Induced and Maintained Clinical Remission in Patients with Crohnʼs Disease Independent of Baseline CRP Concentration
41. Induction, Maintenance, and Sustainability of the Healing of Draining Fistulas in Patients with Crohnʼs Disease Treated with Adalimumab
42. Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohnʼs Disease Who Had Secondary Failure to Infliximab Therapy
43. Review article: high‐dose aminosalicylates to induce and maintain remissions in ulcerative colitis
44. New lessons: classic treatments, expanding options in ulcerative colitis
45. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine
46. Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients
47. Remission and Clinical Response Induced and Maintained in Patients with Active Crohnʼs Disease Treated for 1-Year Open-Label with Adalimumab
48. Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohnʼs Disease in the CLASSIC Study
49. Maintenance of Remission over 1 Year in Patients with Active Crohnʼs Disease Treated with Adalimumab
50. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.